Recent events
Recent events tied to this brand in public sources.
Back to profile14 entries
2021
Perrigo reports third-quarter 2021 financial results
Perrigo announced financial results for the third quarter of fiscal year 2021.
2021
Perrigo lowers 2021 financial guidance
Perrigo said it lowered its earnings guidance amid supply-chain disruption and higher input costs.
2021
Perrigo announced a binding offer to acquire HRA Pharma
Perrigo announced that it had signed a binding offer to acquire HRA Pharma from funds affiliated with Astorg and Goldman Sachs Asset Management for $2.1 billion in cash.
2021
Altaris to acquire Perrigo’s prescription pharmaceuticals division
Altaris Capital Partners announced that it would acquire Perrigo’s prescription pharmaceuticals division for $1.55 billion. The acquisition was expected to close in calendar year 2021, subject to customary closing conditions.
2021
Perrigo announces sale of Generic Rx Pharmaceuticals business
Perrigo announced a definitive agreement to sell its Generic Rx Pharmaceuticals business to Altaris Capital Partners for $1.55 billion. The deal was expected to be completed in the third quarter.
2021
Perrigo announces partnership with Michigan State University
Perrigo announced a formal partnership with Michigan State University to empower consumers to take control of their self-care needs.
2020
Perrigo completes acquisition of three Eastern European brands
Perrigo announced that it had completed its acquisition from Sanofi of the Emolium, Iwostin and Loxon OTC skincare and hair-loss treatment brands.
2020
Perrigo launches store-brand equivalent of Voltaren Arthritis Pain
Perrigo announced it had launched its store-brand equivalent of OTC Voltaren Arthritis Pain to retail partners, and that the product was available nationwide in the United States.
2020
Perrigo announces acquisition of three Eastern European OTC brands
Perrigo announced that it will acquire Emolium, Iwostin and Loxon, three Eastern European OTC skincare and hair-loss treatment brands, from Sanofi. The transaction was expected to close early in the fourth quarter, subject to customary closing conditions.
2020
Perrigo and Kazmira announce CBD partnership
Perrigo announced a strategic investment and long-term supply agreement with Kazmira. The companies plan to scale Kazmira's production of THC-free hemp-based CBD and work toward launching products in global markets; the supply agreement is exclusive for the U.S. store brand market.
2020
Perrigo prices $750 million senior notes offering
Perrigo announced the pricing of a $750 million senior notes offering by its indirect wholly-owned finance subsidiary. The offering was expected to close on or about June 19, 2020, subject to closing conditions.
2020
Perrigo and Tengram affiliates to acquire High Ridge Brands businesses
High Ridge Brands announced that a Perrigo affiliate would acquire its oral care business and a Tengram Capital Partners affiliate would acquire its hair care and skin cleansing business. The transaction was subject to U.S. Bankruptcy Court approval and other closing conditions.
2019
Perrigo completes acquisition of Prevacid®24HR OTC rights
Perrigo announced that it had completed the acquisition of the branded over-the-counter rights to Prevacid®24HR.
2019
Perrigo recalls ranitidine worldwide
Perrigo Company plc announced a voluntary worldwide recall of ranitidine at the retail customer level because of the possible presence of the NDMA impurity.